drugset / Trial / NCT00320697

Smoking Relapse Prevention in Schizophrenia

NCT00320697

Phase 4 Completed 25 enrolled North Suffolk Mental Health Association
RandomizedParallel-groupDouble-blindTreatment

Summary

This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.

Timeline

Start
2006-04
Primary completion
2008-10
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg
Subject Nicotine Unknown 20 mg
Subject Nicotine Unknown 21 mg